Navigation Links
Hard To Treat Diseases (HTDS.PK) Stem Cells and Regenerative Medicine
Date:9/1/2009

PIRAN, Slovenia/BELGRADE, Serbia, Sept. 1 /PRNewswire-FirstCall/ - Hard To Treat Diseases (HTDS.PK) financed the participation of Dr. Ivana Gadjanski in the International Summer School for Stem Cells and Regenerative Medicine held in Piran, Slovenia (21-29. Aug 2009) where a number of eminent speakers presented their work. Among them were Dr. Stephen Minger from King's College, London; Dr. Smadar Cohen from Ben-Gurion University of the Negev, Israel; Dr. Thomas Ekstrom from Karolinska Institute, Stockholm, Sweden; Dr. Zoran Ivanovic from EFS, Bordeaux, France; Dr. Dasa Cziskova from Institute of Neurobiology, Kosice, Slovakia, Dr. Tanja Dominko and Dr. Raymond L. Page from Worcester Polytechnic Institute, USA, Dr. Darja Marolt from Columbia University, USA. Several main topics were discussed: stem cell sources most suitable for clinical application, ethical issues related to stem cell use, obstacles of stem cell therapy (e.g. teratoma formation), future clinical trials (the most interest evokes the FDA-approved world's first human clinical trial of an embryonic stem cell-based therapy for acute spinal cord injury which will be perfomed by Geron using their human embrionic stem cell-derived oligodendrocytes GRNOPC1. The Investigational New Drug Application is currently on clinical hold by the FDA pending the agency's review of new nonclinical animal study data submitted by the company. More information availaible from http://www.geron.com/patients/clinicaltrials/hESC.aspx). Also more technical issues were discussed, e.g. types of biomaterials used for scaffolds, types of bioreactors for growing cells, protocols for cell isolation from various tissues, ways of inducing pluripotency in somatic stem cells (producing iPS), using umbilical cord blood as a source of stem cells. Very promising are adipose-derived stem cells (APC), where first reports are available on the in vivo bone formation and bone augmentation using APC. This type of stem cells raises the least ethical issues and might hold the highest potential for clinical application. However, the takehome message of the whole symposium was that the major task should be to stimulate endogenous potential for repair rather than to force usage of stem cell therapy per se.

The company intends to provide further updates on a timely basis.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard To Treat Diseases Inc that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. Hard To Treat Diseases Inc cautions you that any forward-looking information provided by or on behalf of Hard To Treat Diseases Inc is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard To Treat Diseases Inc's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard To Treat Diseases Inc's control. In addition to those discussed in Hard To Treat Diseases Inc's press releases, public filings, and statements by Hard To Treat Diseases Inc's management, including, but not limited to, Hard To Treat Diseases Inc's estimate of the sufficiency of its existing capital resources, Hard To Treat Diseases Inc's ability to raise additional capital to fund future operations, Hard To Treat Diseases Inc's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard To Treat Diseases Inc's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard To Treat Diseases Inc does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact corporate@htdsmedical.com, www.htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Assessment Quantifies Risks and Benefits of Warfarin Treatment for Atrial Fibrillation
2. Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy
3. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
4. Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
5. Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study
6. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
7. Clinical Study Proves Pollogens TriPollar(TM) Radio Frequency Technology is Effective in the Treatment of Stretch Marks
8. Vectibix(R) Significantly Improved Progression-Free Survival in Second-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer
9. Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss
10. Cancer Centers of North Carolina Offers HDR Brachytherapy for Treatment of Cancerous Tumors
11. Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)...   West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today shared the results of a study highlighting ... intradermal administration of polio vaccines. The study results were ... 2017 by Dr. Ondrej Mach , Clinical Trials ... (WHO), and recently published in the journal Vaccine. ...
(Date:10/4/2017)... Oct. 4, 2017 OBP Medical ... illuminating medical devices, today announced regulatory approval from ... Agency (or Agência Nacional de Vigilância Sanitária (ANVISA)) ... cordless surgical retractor with integrated LED light source ... illumination and exposure of a tissue pocket or ...
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile ... the struggle to reverse the tide of prescription drug addiction. ... regulating their medicine intake and stepping down their dosage in ... to launch in December 2017; the first 100,000 people to ... more at http://www.rebound-solution.com/ ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Dickinson Insurance and ... and financial preparation services, is providing an update on a charitable event that ... City Rescue is a locally recognized nonprofit that provides shelter and care for ...
(Date:10/13/2017)... Pekin, IL (PRWEB) , ... October 13, 2017 ... ... Foundation, which established the certification process to promote standards of excellence for the ... iaedp™ Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at ...
(Date:10/13/2017)... ... 13, 2017 , ... Apple Rehab Shelton Lakes , which specializes in ... the facility as part of a disaster drill on October 3rd. , Apple Rehab ... City Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid ...
(Date:10/13/2017)... Milford, NJ (PRWEB) , ... October 13, 2017 , ... ... weekend at scenic Alexandria Park in Milford, NJ. This free event, sponsored by ... and physical activity. The fun run is geared towards children of all ages; ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
Breaking Medicine News(10 mins):